leading semaglutide class action Evaluating the Cardiovascular Benefits of Innovator 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence Ozempic® Lawsuit | July 2026

It is approved for type 2 diabetes and chronic weight management in adults with obesity or overweight with weight-related comorbidities, conditions often associated with insulin resistance

These reactions differ fundamentally from burping and represent a contraindication to GLP-1 therapy entirely

The dual effect on appetite and insulin makes semaglutide a valuable choice for many

The key question is not whether 20 units is too much in the abstract

In fact, for some people weight loss can seem almost impossible no matter how hard they try

Lancet 330(8571):13001304 Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5